

---

# Subject Index

---

- Accounting systems: Comptes Nationaux de la Santé, France, 35; cost-of-disease accounts, 36–42, 51; economic growth accounting, 115; mental health expenditure account, 69–72; national accounts, 29–32; national health accounts, 32–36
- Acute myocardial infarction (AMI): advanced cardiovascular life support (ACLS), 385–86; defined, 313; incidence and case fatality rates, 366–67; incidence and mortality rates, 27–30, 93, 326–27, 329, 370–74; length of life after, 326–27; life expectancy after, 332; medical background for, 313–14; readmission rates within one year of, 335–39. *See also* Ischemic heart disease (IHD)
- Acute myocardial infarction (AMI) treatment: ACE inhibitors, 365, 381; acute revascularization, 380; aspirin, 376; beta blockade, 376; calcium channel blockers, 376; for cardiac arrest, 386, 388; changes in, 314, 318–21, 365–69; coronary artery bypass graft (CABG), 379–80; cost-effectiveness of, 369–402; effect of acute, 327–29; heparin, 378; lidocaine, 378–79; magnesium, 379; nitrates, 378; post-acute care and outcomes, 393–95; prices of, 318–19; primary PTCA, 379; pulmonary artery catheterization, 380; thrombolysis, 374, 376
- Agency for Health Care Policy and Research (AHCPR), 485
- Ambulatory Care Group algorithm, 165, 468
- American Hospital Association (AHA): Annual Survey, 278–79, 283, 287–89, 292; Guide, 229–30; *Hospital Statistics*, 282; National Hospital Panel Survey, 278–79, 282–83
- American Medical Association (AMA): Group Practice File, 239; Physician's Masterfile, 239
- AMI. *See* Acute myocardial infarction (AMI)
- Boskin Commission: on CPI pricing of health care inputs and outcomes, 471; measurement recommendation to BLS, 150n17; on pricing medical care outcomes, 190–91
- Bureau of Economic Analysis (BEA): NIPA data on health care spending, 271; *Survey of Current Business*, 287; use of PPI health care indexes, 256
- Bureau of Labor Statistics (BLS): construction of medical care CPIs and PPIs, 156–86; hospital index sample selection, 229–31; index of medical prices, 428, 433; International Price Program (IPP), 160, 176; mental health care expenditures price indexes, 62–69; pricing procedures for medical treatments, 470–71; research related to pricing medical care outcomes, 190–91; use of fixed weights by, 471. *See also* Consumer

- Bureau of Labor Statistics (BLS) (*cont.*)  
 Price Index (CPI); Data sources; Medical care CPIs (MCPIs); Medical care PPIs (MPPIs); Producer Price Index (PPI)
- Case fatality rates (CFRs): in AMIs, 366–67; changes in, 367–69; for hospitalized heart attack patients, 370–74
- Cataract surgery: changes in cost of, 417, 435; criteria for, 415–17, 419–25; increased rates of, 418–19; intraocular lens (IOL) insertions, 414–15, 417–18; valuing benefits of, 425–27, 435
- Cataract treatment: changes in surgical techniques for, 414–15, 417–18; flow of services related to, 434; lessons from, 435–36; summary of, 415–16; valuing extraction of, 422–25, 435
- Census of Governments (COG), 276, 286, 288
- Census of Service Industries (CSI), 275–76, 282, 288–89
- Child health: improvements in, 511; production model, 513, 517–32
- Children: health environment for (1960–90), 518; legislation affecting, 514–15; mortality from injury model, 513, 519–20, 522–32; trauma care for injuries, 516
- Child safety: changes in production of, 529–32; information about, 514–18, 534; information in regulation about, 514–16; mortality rates related to, 511–12
- Chronic conditions: data on, 578–79; prevalence and severity of, 584–87
- Classifications: of antidepressant medications, 478; Current Procedural Terminology (CPT4) codes, 467–68; of diseases in CRISP database, 572–74; of diseases in DRGs, 40–41; of hospitals in SIC and DRG, 228–31; International Classification of Diseases, 37–41, 165, 467–68, 476–77, 512; North American Industrial Classification System, 221–22, 229, 238, 245, 250, 252; in treatment of depression, 479–80
- Cognitive dissonance, 103–4
- Competition: in drug industry, 247; between nonprofit and for-profit firms, 120. *See also* Price competition
- Comptes Nationaux de la Santé, France, 35
- Consumer Expenditure Survey (CEX): budget shares in, 185; composition of, 207n7; expenditure weights in CPI from, 204, 207–10, 469; medical care component, 209; role in construction of CPI, 157–59; weights for product categories, 183–85
- Consumer Price Index (CPI): construction of medical care CPIs, 156–86; CPI for urban consumers (CPI-U), 203, 206, 209; CPI for urban workers (CPI-W), 203; expenditure comparison with PCE, 206; health insurance price change measurement, 214, 216–17; hospital index, 212–14; hospital services in (1998), 179–83; hypothetical cataract index, 427–31; medical care component, 16, 60–62, 205–6; medical care products and services in, 177–86, 203–4, 210–14, 428; Medicare prices and services in, 206; mental health care price indexes in (1990s), 62–63; nursing home and adult daycare index, 213; out-of-pocket prices in, 220, 308; physicians' fee component, 61n27, 63; published medical care indexes, 214–15; quality adjustment in, 17; substratum hospital indexes, 213; summary of, 156–59; use of entry-level items (ELIs), 158, 180; weighting issues in, 182–86. *See also* Medical care CPIs (MCPIs); Medicare
- Consumer Product Safety Commission standards, 514, 535
- Consumer welfare: measurement in drug products model, 542–48. *See also* Patients
- Cooperative Cardiovascular Project (CCP), 366, 393–94, 401
- Coronary artery bypass graft (CABG), 314
- Coronary Heart Disease model, 364
- Cost-effectiveness: of AMI treatments and medical intervention, 369–402; analysis of health care industry, 25–26, 52; measurement of medical costs in analyses of, 105–10; of mental disorder treatment, 505–6; Panel on Cost-Effectiveness in Health and Medicine, 98, 114; profit maximization of firms, 121–23; using QALYs for analysis, 99–100. *See also* Health care outcomes; Output; Quality-adjusted life years (QALYs); Revealed preference theory
- Cost indexes: prototype of cataract surgery index, 427
- Cost-of-disease accounts: comparisons and

- trends, 42–51; studies and data in, 36–42, 51
- Cost-of-living index: construction of, 310–13, 352–53, 431–35; for heart attack (1984–94), 326–35; for heart attack including quality of life, 341–42; QALYs in, 426
- Costs: of cataract surgery, 417, 435; Diagnostic Cost Group, 165; future cost-effectiveness, 105–11, 114; of long- and short-term nonprofit industries, 126–27; for R&D in nonprofit firms, 129; to treat illness, 17–18; to treat mental illness, 60–72, 74–75; of treatment in spending price index, 188–90. *See also* Cost-effectiveness; Health care expenditures
- CSI. *See* Census of Service Industries (CSI)
- Current Procedural Terminology (CPT4), 164–65, 478–79
- Data sources: American Hospital Association (AHA), 275, 278, 287–88; for analysis of DMARD market, 449–51; Census of Governments (COG), 276, 286, 288; Census of Service Industries (CSI), 275–76, 288–90; for children's mortality from injury analysis, 520–22; Computerized Retrieval of Information on Scientific Projects (CRISP), 567–68, 571–74; Cooperative Cardiovascular Project (CCP), 366, 393–94, 401; in cost-of-disease accounts, 51; Current Population Survey (CPS), 520–21; Governmental Finance (GF) survey, 276, 286; Health Care Financing Administration, 183; for health care spending, 271; IMS America Inc., 248–49, 449, 461; Medical Expenditure Panel Survey (MEPS), 192; MEDSTAT, Inc., 237, 476–81, 488, 498, 499, 506; National Comorbidity Survey, 506; *National Drug and Therapeutic Index* (NDTI), 450–51, 459, 461; National Health Accounts (NHA), 271–72; National Health and Nutrition Examination Survey (NHANES), 395; National Health Interview Survey (NHIS), 336, 576–78; National Hospital Discharge Survey (NHDS), 366–67; National Income and Product Accounts (NIPA), 271–72; National Mortality Detail Files, 520, 576; National Register of Myocardial Infarction (NRM1), 374, 378, 392; Point of Purchase Survey (POPS), 210–11; for pricing of heart attack treatment, 314–18; for state and local government expenditures, 286; Worcester Heart Attack Study, 374, 378, 379, 390
- Depression: characterization of, 471; Depression Guideline Panel, 482; Medical Outcomes Study (MOS), 484–85; mild or moderate, 472
- Depression, major: antidepressant medications classification, 478; diagnosis of, 471–72; drug products to treat, 473–75; electroconvulsive therapy (ECT), 474–75; incidence of, 472–73; treatment for acute phase, 473–76; treatments and treatment bundles for, 473–89
- Diagnostic Cost Group: Hierarchical Coexisting Conditions model, 165, 468
- Diagnostic-related groups (DRGs): as disease classification system, 40–41; frequency counts from HCUP, 232; grouping in MDCs, 231; Medicare prospective payment schedules under, 164–65; PPI use to price services, 231–34; state-regulated programs, 181
- Disability-adjusted life years (DALYs), 335n22
- Disease burden concept: data on, 576–79; in model of research spending, 567–72
- Diseases: burden-of-disease study, 37; classification in CRISP database, 572–74; cost-of-disease studies, 36–42; diagnosis-related groups (DRGs), 40–41; expenditure by, 43–51; insurance disease management plans, 165–66; International Classification of Diseases (ICD), 37–41, 165, 476–77, 512; model of research expenditure at level of, 568–72. *See also* Chronic conditions; Classifications; Cost-of-disease accounts; Diagnostic-related groups (DRGs); International Classification of Diseases (ICD); Ischemic heart disease (IHD)
- DMARDs. *See* Drug products
- DRGs. *See* Diagnostic-related groups (DRGs)
- Drug industry: definition of, 245; product innovation and research in, 539–48, 567–72
- Drug products: consumption of DMARDs by diagnosis, 450–51; corticosteroids,

Drug products (*cont.*)

- 443–44; CPI treatment of prices for, 211–12; demand in DMARD market, 447–52; disease-modifying antirheumatic drugs (DMARDs), 442–44; drug switching in treatment, 480–81; immunosuppressants, 444; model of prescription choice and patient welfare, 540–48; monoamine oxidase (MAO) inhibitors, 474–75; national drug codes (NDC), 478; new and generic products in PPI, 247–50; nonsteroidal anti-inflammatory drugs (NSAIDs), 442, 444; patient benefits from innovative, 539–48; price indexes, 245–50; quality of rheumatoid arthritis drug treatment, 444–49; selective serotonin-reuptake inhibitors (SSRIs), 474, 475–76, 480; serotonin-norepinephrine reuptake inhibitors (SNRIs), 480; for treatment of rheumatoid arthritis, 439–40, 442–44, 458–61; tricyclic antidepressants (TCAs), 474, 475–76. *See also* Acute myocardial infarction (AMI) treatment
- Economic growth accounting, 115  
ELIs (entry-level items). *See* Consumer Price Index (CPI)
- Exclusive provider organizations (EPOs), 242
- Expenditures by disease: international comparisons of, 43–48; trends in U.S., 49–51
- FDA. *See* Food and Drug Administration (FDA)
- Food and Drug Administration (FDA): approval process of, 245–48, 485
- For-profit firms: behavioral difference from nonprofits, 222–23; choice of for-profit status by, 124–27; incentives for R&D investment, 129; long-term productivity patterns of, 129–35; output decisions of, 223–24; productivity of, 119
- Governmental Finance (GF) survey, 276, 286
- Gross domestic product (GDP): as aggregate of NIPA account, 279–80; benchmark input-output estimates of, 287; measurement of, 280; medical care industry share of, 348–49; PPI in deflator for, 268
- Gross product originating (GPO), 287
- Health: child health production model, 513, 517–32; medical and nonmedical influences on, 21; production and utility functions in, 146–49; time in production of, 148
- Health care: cost-effectiveness studies, 25–26; economic growth accounting applied to, 115–16; patient-doctor relationship, 143, 145; price exogeneity of productivity in, 222–23; production of, 119. *See also* Health care sector; Home health care; Medical care; Medical care CPIs (MCPIs); Medical care PPIs (MPPIs)
- Health care expenditures: accounting systems for, 29–42; comparison of CPI and PCE for, 206; in cost of disease accounts, 36–52; federal outlays for, 348–49; international comparisons, 43–48; new price index for, 188–93; in NHA and NIPA, 300–302; trends in United States (1963–95), 49–51. *See also* Mental health care expenditures
- Health Care Financing Administration (HCFA): NHA data on health care expenditures, 271; reimbursement for acute care hospitals treating Medicare patients, 164
- Health care outcomes: associated with medical intervention, 21–22, 25–26; Association for Pharmaceutical Outcomes Research, 97–98; in cost-effectiveness studies, 52; defined, 25; disease-specific, 72–73; in heart attack care, 306; information on health care, 19; in measurement of price change, 217–18; measures of, 26, 101–2; Medical Outcomes Study of depression, 484–85; patient choice associated with, 548–52; pricing medical treatments, 470–71; pricing of, 190–91, 471. *See also* Output; Productivity
- Health care sector: assessment of productivity in, 141–42; cost-effectiveness studies in, 52; differences between nonprofits and for-profits in, 119–20; effect of new goods and changes in, 225–27; marketplace of, 144–49; measuring output of, 1, 15–29, 347; organizational types in, 222; output decision making in, 223; output in publicly provided, 72; price index research for, 52–53; price measurement in, 2–8; productiv-

- ity of, 119; subsectors providing goods and services, 144. *See also* Cost-effectiveness; Health care outcomes; Output
- Health insurance: disease management programs of, 165–66; industry price index, 255; moral hazard in, 28, 143, 145, 351; out-of-pocket expenditures associated with, 177–78; physicians' reimbursement from private, 242; pricing of, 18–19, 192, 205, 214–15
- Health maintenance organizations (HMOs): reimbursement to physicians by, 242
- Healthy-year equivalents (HYEs), 335n22
- Heart attack. *See* Acute myocardial infarction (AMI)
- Hedonic price analysis: of arthritic drugs, 439–57; in formation of medical care price index, 153–54; at medical insurance plan level, 154–55
- Hedonic price indexes, 492–96
- Home health care: PPI index, 254; price-determining characteristics, 255; primary services associated with, 254
- Hospital industry: comparison of data source estimates in, 289, 291; expenditures in AHA Annual Survey, 278–79; input-output estimates for NIPA, 281; NHA and NIPA estimates of spending for, 289, 291–92; other-than-treatment revenues, 234; price competition in, 223; SIC definition of, 228–29; spending for care in NHA and NIPA, 272–76
- Hospitalization: for cataract treatment, 415–16; characteristics and reporting of AMI, 389–93; for heart attack, 315, 365–70, 388–90; in-hospital treatment for AMI, 374–85; readmission for IHD, 335–36, 338f; related to DRGs, 165
- Hospital price indexes, 228–38
- IHD. *See* Ischemic heart disease (IHD)
- Illness: cost of treating, 17–18; future costs of unrelated, 105–11, 114. *See also* Chronic conditions
- Information: in R&D, 534–35, 537–38; in regulation, 514–16
- Innovation: change in quality with, 225–27; in pharmaceutical industry, 539–48
- International Classification of Diseases (ICD), 37–41, 165, 476–77, 512, 568–72
- International Price Program (IPP), 160, 176
- Ischemic heart disease (IHD): age-adjusted mortality rates for, 363–64; characteristics of population with, 339; readmission to hospital for, 335–36, 338f; self-reported health status with and without, 339–41; treatment for, 364–65
- Laspeyres price index: cost-of-living, 312–13; CPI calculations based on, 158; formulas to calculate aggregate PPIs, 161–62; perspective of, 227–28
- Legislation: related to children's health and safety, 514–16
- Long-term care: productivity decisions in, 129–35, 138–40
- MCPIs. *See* Medical care CPIs (MCPIs)
- Medicaid: government spending under, 348–49; as percent of physician revenue, 241–42; reimbursements to nursing homes, 253
- Medical care CPIs (MCPIs): aggregate and subindexes for, 177, 469; alternatives to, 17–18; BLS procedures for, 469–70; construction of, 16–17, 156–86, 351; health care outcomes in, 16–17; hospital services, 469–70; inclusions and exclusions, 183; item structure for, 179; market environment underlying, 144–56; medical care products in, 177–86; physician services, 469–70; prescription drug component in, 181–82; proposed pricing of package treatments, 470; recent changes in, 470; revisions (1998), 180–81; weighting, 178, 182–86
- Medical care PPIs (MPPIs): BLS procedures for, 466–69; construction of, 156–86, 351; hospital services in, 171–73, 468–69; market environment underlying, 144–56; output measurement in, 163–66; physicians' services in, 166–71, 468–69; prescription drug component in, 173–77, 181
- Medical care price indexes: adjustment for new goods and product changes in, 225–26; of Bureau of Labor Statistics, 19, 204; for cataract surgery, 18; construction of, 307–8, 352–53; cost-of-living index, 310–13, 326–42; issues in construction of, 343–45, 352–53; measurement of, 465–71; methods to form, 153–56; proposed expenditure price

- Medical care price indexes (*cont.*)  
 index, 188–91; research initiative for, 19; service price indexes, 309–10, 321–26; uses for, 142. *See also* Medical care CPIs (MCPIs); Medical care PPIs (MPPIs)
- Medical care sector: construction of medical care CPIs and PPIs, 142–43; markets in U.S., 144–49; output of, 149; pricing of services in, 143, 149–53, 187–88, 199–200; services in MPPIs, 163–77; third-party and out-of-pocket payments, 145–46; uniqueness of services in, 146–47
- Medical Expenditure Panel Survey (MEPS), 192
- Medical insurance. *See* Health insurance
- Medical interventions: health as output of, 21–25; health care outcomes from, 25–26; for ischemic heart disease, 363–64; measuring health implications of, 25; nonmedical interventions as substitute for, 538; resources required by, 21. *See also* Medical treatment
- Medical laboratory industry, 250–52
- Medical outcomes. *See* Health care outcomes
- Medical Outcomes Study (MOS) (of depression), 484–85
- Medical sector. *See* Health care sector
- Medical treatment: alternative treatment bundles, 485–89, 506; for AMI, 314–35, 365–402; BLS pricing of, 470–71; for cataracts, 415–16, 434–36; for depression, 473–89; for IHD, 364–65; PPI definition, 224; proposed package treatment prices, 470. *See also* Mental health care
- Medicare: government spending under, 348–49; Medicare Payment Advisory Commission, 164; as percent of physician revenue, 241; post-heart attack spending, 332t, 333–34; prices and services in CPI, 206; prospective payment schedules, 164; reimbursements to nursing homes by, 253; use of DRG system, 164
- Mental health care: adjusted price indexes for, 63–69; components in growth in expenditures for, 58–59; growth rates and price indexes for services, 79–81t. *See also* Depression; Depression, major
- Mental health care expenditures: account for, 69–72; BLS price indexes for, 62–69; deflation methodology for, 58–69; match between price indexes and, 59–60, 83–88t; price index, 60–62; trends in U.S. for, 53–58, 76–77t
- Minneapolis community study, 373, 386
- Minnesota data, 376, 378, 379, 389, 390, 395
- Moral hazard: caused by health insurance, 28, 143, 351; in medical care market, 145
- Morbidity: National Comorbidity Survey, 506; in QALY health care outcome measure, 26
- Mortality rates: with acute in-hospital treatment for heart attack, 374–85; among children, 511, 520–22; children's injuries, 516, 532–35; hazard rates, 331–32; after heart attack, 326–27; potential life years lost (PLYL), 579–84; premature deaths, 578–84; in QALY health care outcome measure, 26. *See also* Case fatality rates (CFRs)
- Mortality rates, heart attack: effect of acute treatment on, 27–30, 93; effect of drug therapies on, 329; for hospitalized patients, 370–72; postacute mortality, 327f, 330
- MPPIs. *See* Medical care PPIs (MPPIs)
- National Comorbidity Survey, 506
- National Death Index, 372
- National Drug Code (NDC) designation, 249
- National Health Accounts (NHA): aim of, 276; federal hospital expenditures, 279–80; hospital care estimates, 277; medical services included in, 256, 271; national expenditures on health in, 32–36, 271–72, 276–77; physician services defined, 293–95; policy issues, 271; total spending for hospital care, 272. *See also* National Income and Product Accounts (NIPA)
- National Health Interview Survey (NHIS), 336
- National Heart Attack Alert Program, 401
- National Hospital Discharge Survey (NHDS), 366
- National Income and Product Accounts (NIPA): annual aggregate series of PCE for hospitals, 281–84; expenditures on health care in, 30; federal hos-

- pital expenditures, 284–86; health care spending estimates, 271, 273; input-output (1987), 281; personal consumption expenditures (PCE), 30; physicians' services, 295–96; use of Fisher price index in, 70–71
- National Institutes of Health (NIH): CRISP database, 567, 571–74; funding for research, 567; indexing terms of Division of Research Grants, 572–74; institutes and centers, 565–67; National Institute of Mental Health, 484–85
- National Mortality Detail Files, 520
- NHA. *See* National Health Accounts (NHA)
- Nonprofit firms: behavioral difference from for-profit firms, 222–23; choice of nonprofit status by, 124–27; in health care sector, 119, 222; productivity decisions of, 223–24; productivity in long-term care, 129–35, 138–40; R&D in, 120, 127–29
- North American Industrial Classification System (NAICS), 221–22; drug industry in, 245; hospital industry in, 229; medical laboratories in, 250; nursing homes in, 252; physician industry in, 238
- North Carolina study, 388
- Nursing homes: in CPI, 213; factors affecting prices, 253; Medicare and Medicaid reimbursements to, 253; in NAICS, 252; Nursing Home Index, 252–54; output and price in PPI, 253–54
- Outcomes. *See* Health care outcomes
- Out-of-pocket payments (self-pay): in MCPIs, 469; as percent of physicians' revenue, 242; PPI definition of, 242n28. *See also* Health insurance; Medical care CPIs (MCPIs)
- Output: of car repair, 26–29; DRGs as concept for, 467; of firm, 224; of health care sector, 21–25, 308; health gains as, 1; of home health care for PPI, 254–55; of hospitals, 231–38; of medical laboratories for PPI, 251–52; of nonprofit and for-profit sectors, 120, 223; of nursing homes for PPI, 253–54; of pharmaceutical industry for PPI, 246–50, 539; of physician services for PPI, 241–45. *See also* For-profit firms; Health care outcomes; Nonprofit firms; Productivity
- Output measures: construction for medical care, 51; in health care sector, 1–8, 26–29, 142–43, 308; in nonmedical services, 19–21; obtaining, 59; in public health care systems, 72–73; in service industries, 15–16
- Output price indexes, 227–28
- Paasche price index perspective, 227–28
- Patients: cognitive dissonance of, 103–4; compliance with physician's drug therapy, 541–48; compliance with physician's prescription choice, 548–52; in model of choice of drug products, 539–48; outpatient services for cataract surgery, 415–18; QALYs as measure of preferences of, 100–105, 110–14; relationship with physician, 143, 145–46; welfare based on compliance with drug therapy, 552–57, 560–63; willingness to pay, 17–19, 29, 104–5, 426–27, 460. *See also* Acute myocardial infarction (AMI) treatment; Hospitalization; Revealed preference theory
- PCE. *See* Personal consumption expenditures (PCE)
- Percutaneous transluminal coronary angioplasty (PTCA), 314, 328–29
- Personal consumption expenditures (PCE): comparison with CPI, 206; defined, 280; estimates for physicians' services, 295–96; for government hospitals, 283–84; for hospital care, 280–87; in NIPA accounts, 30, 34; for physicians' services, 293; for proprietary hospitals, 282–83
- Pharmaceuticals. *See* Drug products
- Physician price indexes, 238–45
- Physicians: authority over prescription choice, 548–52; government spending for services of, 293–97; in model of choice of drug products, 539–48; patient's compliance with prescription choice of, 552–57, 560–63; physician industry defined, 238; relationship with patient, 143, 145–46
- Physician services: in MCPIs and MPPIs, 469–70; NHA and NIPA estimates, 293–97; payment for, 241–43; Physicians Services Price Index, 238–45; pricing of, 241–45
- Point of Purchase Survey (POPS), 210–11

- Point-of-service (POS) providers, 242
- Preference measures: revealed preference principle, 104–5, 110–11; willingness to pay, 104–5
- Preferred provider organizations (PPOs), 242
- Price change: CPI health insurance price change measurement, 214, 216–17; input and outcomes approaches to measurement of, 217–18; measurement in CPI of medical care, 217–18
- Price competition: among third-party payers, 223; in hospital industry, 223
- Price indexes: aggregate indexes for treatment of depression, 489–92; for auto repair, 19–20; Laspeyres price index, 158; MCPIs and MPPIs, 4; new index for mental health treatment spending, 59–62, 82t; output price index, 227–28; PPI and CPI mental health treatment spending, 59–63. *See also* Hospital price indexes; Medical care price indexes
- Price inflation: in MCPI and MPPi (1927–96), 177–78; overstatement in CPI for hospitalization, 179
- Prices: BLS International Price Program (IPP), 160, 176; exogenous output prices, 222–23; of health insurance, 155–56, 255; of home health care for PPI, 254–55; of hospitals in PPI, 231–38; medical care price data, 314–18; of medical care services, 149–53; of medical laboratories for PPI, 251–52; for medical treatment, 224; of nursing homes for PPI, 253–54; of pharmaceutical industry for PPI, 246–50; of physician services for PPI, 241–45; of treatment bundles for depression, 485–89, 506
- Producer Price Index (PPI): conceptual framework of, 222; definition of treatment in, 224; drug price indexes, 245–50; health care price indexes, 63; hospital price indexes, 63, 228–38; for industries associated with health care, 163; for mental health care treatment, 63; Nursing Home Index, 252–54; Physicians Services Price Index, 238–45; for prescription pharmaceuticals, 469; pricing services paid by Medicare, 231–34; publication structure for drug, 262–66; publication structure for health services, 257–61; sampling procedure, 230n17; summary of, 160–63; underlying concept of, 189. *See also* Medical care PPIs (MPPIs)
- Productivity: in car repair (1973–93), 94–95; differences in long-term care, 129–35, 138–40; differences in mixed industries, 124–27; in long-term care, 129–35, 138–40; in nonprofit and for-profit sectors, 119; output measurement to assess, 141–42; property rights theory related to, 120–21, 127–29; of research across diseases, 570–72. *See also* Cost-effectiveness; Health care outcomes; Output
- Property rights theory, 120, 127–29, 135
- PTCA. *See* Percutaneous transluminal coronary angioplasty (PTCA)
- Quality-adjusted life years (QALYs): assessing validity of, 100–105; in cost-of-living index, 426; as health care outcome measure, 26; loss with rheumatoid arthritis, 441; medical cost-effectiveness analysis using, 99–100
- Quality of life: cost-of-living index for heart attacks with, 341–42; dimensions to, 335; for heart attack patients, 335
- Receiver operating characteristic (ROC) curve, 102–4
- Regulation: highway safety, 514; related to consumer protection and child safety, 514–19
- Research and development (R&D): distribution of private funding for, 574n13, 575f; grants to study chronic conditions, 584–87; information about injury prevention, 534–35, 537–38; investments in quality-enhancing, 129; by nonprofit firms, 127–29; research funding allocation model, 567–72
- Revealed preference theory: to analyze medical care, 353; to assess validity of QALYs, 98–105, 110–11, 113–14; correct application of, 353–55; to measure consumer welfare, 542–43; in medical care index construction, 351–52; in model of patient-physician choice of drug products, 542–48
- Rheumatoid arthritis (RA): causes of, 441;



- measuring drug treatment quality for, 444; symptoms of and treatment for, 439–41, 449–50
- Seattle study, 386
- Service price indexes (SPIs): derivation of, 309–10; disaggregated and aggregated, 321–26
- Standard Industrial Classification (SIC): hospital classifications in, 228–31; medical lab definition, 250. *See also* North American Industrial Classification System (NAICS)
- System of National Accounts (SNA), 30, 36
- Technological change: as cause of high cost of medical care, 349; change in quality with, 225–27; effect on cost of supplying medical care, 361; knowledge as, 147–48; progress in cataract surgery, 413; significance in medical care sector, 143
- Third-party payers, 223
- U.S. Bureau of the Census: *County Business Patterns* report, 286; Point of Purchase Survey (POPS), 210–11; *Public Employment* survey, 286
- U.S. Department of Defense (DOD), Defense Health Program, 285–86
- U.S. Department of Health and Human Services (USDHHS): Agency for Health Care Research and Quality (AHRQ), 165
- Value of life: compensating differentials to estimate, 333; contingent valuation to estimate, 332–33; with increased life expectancy, 343; value of increased longevity, 332t, 333–34. *See also* Quality of life
- Welfare economics: link between cost-effectiveness and, 99
- Wholesale Price Index (WPI), 160
- Willingness to pay: for car repair, 27; for health care, 17–19, 29; as preference measure, 104–5; for a quality-adjusted life year, 426–27; using hedonic analysis to assess, 460
- Worcester Heart Attack Study, 374, 378, 379, 390